PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-3.43%
Cash & equivalents declining -3.43% while CRVO's grows 2.42%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-3.43%
Below half of CRVO's -14.96%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
967.92%
Other current assets growth < half of CRVO's -9.44%. David Dodd sees a leaner approach to short-term items.
-3.05%
Below half of CRVO's -14.73%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
0.98%
Higher PP&E (Net) Growth compared to CRVO's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Non-Current Assets Growth compared to CRVO's zero value, indicating worse performance.
0.98%
Higher Total Non-Current Assets Growth compared to CRVO's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-2.92%
Below half of CRVO's -14.73%. Michael Burry sees a potential red flag for stagnation or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-106.99%
Exceeding 1.5x CRVO's -68.66%. Michael Burry suspects ballooning short-term obligations vs. competitor.
16.37%
Less than half of CRVO's -31.09%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.35%
Higher Total Non-Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
2.58%
Less than half of CRVO's -31.09%. David Dodd sees far fewer liability expansions relative to competitor.
3.85%
Higher Common Stock (Book Value) Growth compared to CRVO's zero value, indicating worse performance.
-5.06%
≥ 1.5x CRVO's -1.41%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.22%
0.5-0.75x CRVO's -12.59%. Martin Whitman is wary of lagging equity growth vs. competitor.
-2.92%
Below half CRVO's -14.73%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-5.00%
Less than half of CRVO's -100.00%. David Dodd sees less overall debt expansion vs. competitor.
3.39%
Less than half of CRVO's -385.49%. David Dodd sees better deleveraging or stronger cash buildup than competitor.